NDC 50090-5960-01 - Losartan Potassium and Hydrochlorothiazide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-5960
- Requested NDC
- 50090-5960-01
- Package NDCs from labels
- 50090-5960-0, 50090-5960-2, 50090-5960-1, 50090-5960-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2024-05-06
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Losartan Potassium and Hydrochlorothiazide - A-S Medication Solutions | A-S Medication Solutions | 2024-05-06 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-5960-0 | Losartan Potassium and Hydrochlorothiazide | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 7 | |
| 50090-5960-1 | Losartan Potassium and Hydrochlorothiazide | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 7 | |
| 50090-5960-2 | Losartan Potassium and Hydrochlorothiazide | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 7 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-5960 | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE) TABLET, FILM COATED [A-S MEDICATION SOLUTIONS] | 7 | Current NDC, Legacy NDC, 3 package rows | 20240511_1bb08103-04ee-47a6-a9ad-290e169feb51.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-5960-0 | EA - Each | 50090-5960 | 236055f1-416d-4476-9b0a-73e1e0487b4e | 1 | 2022-07-06 |
| 50090-5960-1 | EA - Each | 50090-5960 | 7d68ca49-dafa-447b-a05c-8d0bc0a3e141 | 1 | 2022-07-06 |
| 50090-5960-2 | EA - Each | 50090-5960 | 4e10ae2d-dd32-475b-9ed6-a7938f3dac25 | 1 | 2023-04-07 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Yves Saint Laurent All Hours Foundation Broad Spectrum SPF 30 Sunscreen Luminous Matte Foundation | OCTINOXATE AND TITANIUM DIOXIDE | L'Oreal USA Products Inc | 43539766-2e70-4b42-b64b-1d30367b2eb9 | 2024-06-24 | Warnings | 15FIX9V2JP |
| Exel Clarifying Line SPF 50 | OCTINOXATE, OCTOCRYLENE, OXYBENZONE, TATANIUM DIOXIDE | Biocosmetica Exel Argentina SRL | e65a68f6-d1b7-4cbf-a3f8-5cc04036221a | 2024-06-23 | Warnings | 15FIX9V2JP |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 9c0809dc-cbdd-1a33-e053-2995a90a4825 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 9f1c20aa-2028-412d-e053-2995a90a1368 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | a11075f1-f7d0-0c3d-e053-2995a90a0c9d | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | NuCare Pharmaceuticals,Inc. | a111cb8f-a100-a05d-e053-2995a90a020c | 2024-06-20 | Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | a1123700-f4c7-2b62-e053-2a95a90a87d6 | 2024-06-20 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 9130921b-02f0-82d6-e053-2995a90a9c0a | 2024-06-19 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 91305ca4-7d56-2052-e053-2995a90a5d61 | 2024-06-19 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 97a50b38-f5b3-0a96-e053-2995a90a345f | 2024-06-19 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 8c2b3412-254b-8fa9-e053-2a95a90a7dc6 | 2024-06-18 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Protectif Fair Tint | ZINC OXIDE AND TITANIUM DIOXIDE | Derma Research Group Inc. | 1a8c8804-1d6b-b5a5-e063-6394a90a1260 | 2024-06-18 | Warnings | 15FIX9V2JP |
| benazepril hydrochloride and hydrochlorothiazide | BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | Bryant Ranch Prepack | f4120568-dd9b-47a5-bd44-4de6ed343bbe | 2024-06-18 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Valsartan and Hydrochlorothiazide | VALSARTAN AND HYDROCHLOROTHIAZIDE | Aurobindo Pharma Limited | c5bc7c55-b50c-4e61-ad1f-5ebb607c262f | 2024-06-15 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Protectif Untinted | ZINC OXIDE AND TITANIUM DIOXIDE | Derma Research Group Inc. | 1acd3f09-87f2-75e4-e063-6394a90a0cd9 | 2024-06-13 | Warnings | 15FIX9V2JP |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | NuCare Pharmaceuticals,Inc. | 7e7cb50d-c984-5c01-e053-2a91aa0a68a5 | 2024-06-12 | Warnings, Adverse reactions | 0J48LPH2TH |
| Lisinopril and Hydrochlorothiazide | LISINOPRIL AND HYDROCHLOROTHIAZIDE | NuCare Pharmaceuticals,Inc. | 6c57bf12-9ad5-3a25-e053-2a91aa0aaf26 | 2024-06-10 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium | LOSARTAN POTASSIUM | NuCare Pharmaceuticals,Inc. | 6eec2a4c-6b5c-11a5-e053-2991aa0aa56b | 2024-06-10 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | NuCare Pharmaceuticals,Inc. | 72c97b7f-d945-5106-e053-2a91aa0a9b3b | 2024-06-10 | Boxed warning, Warnings, Adverse reactions | 979471 3ST302B24A 0J48LPH2TH |
| Valsartan and Hydrochlorothiazide | VALSARTAN AND HYDROCHLOROTHIAZIDE | Alembic Pharmaceuticals Inc. | 973973a3-9fec-4afc-910f-187f099dfe2d | 2024-06-10 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.